Correction to: a Phase 2 Study of 16α-[18F]-Fluoro-17β-Estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC) (Molecular Imaging and Biology, (2014), 16, 3, (431-440), 10.1007/s11307-013-0699-7);A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC)

Molecular Imaging and Biology

Volumn 16, Issue 3, 2014, Pages 431-440

  Peterson, Lanell M ^a   Kurland, Brenda F ^b,c   Schubert, Erin K ^a,d   Link, Jeanne M ^a   Gadi, V K ^a,b   Specht, Jennifer M ^a,b   Eary, Janet F ^a   Porter, Peggy ^b   Shankar, Lalitha K ^e   Mankoff, David A ^a,d   Linden, Hannah M ^a,b  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Endocrine therapy; ER expression; FDG PET; FES PET; Metastatic breast cancer; Response

Indexed keywords

16ALPHA FLUOROESTRADIOL F 18; ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; EXEMESTANE; FLUORODEOXYGLUCOSE F 18; FULVESTRANT; LAPATINIB; LETROZOLE; RADIOPHARMACEUTICAL AGENT; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG; ESTRADIOL; FLUORINE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; HORMONE SENSITIVITY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; METASTASIS; PET SCANNER; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR BIOPSY; BREAST TUMOR; CLINICAL TRIAL; DIAGNOSTIC USE; PATHOLOGY; PROCEDURES; SCINTISCANNING;

BREAST NEOPLASMS; ESTRADIOL; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY;

EID: 84902533319     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-018-1287-7     Document Type: Erratum

References (36)

1. DeSantis C, Siegel R, Bandi P, Jemal A (2011) Breast cancer statistics. CA Cancer J Clin 61(6):409-418
2. Chia SK, Speers CH, D'Yachkova Y et al (2007) The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 110(5):973-979
3. Carlson RW (2002) Sequencing of endocrine therapies in breast cancer - integration of recent data. Breast Cancer Res Treat 75(Suppl 1):S27-S32, discussion S33-S25
4. Major MA (2003) Clinical trials update: medical management of advanced breast cancer. Cancer Nurs 26(6 Suppl):10S-15S
5. Carlson RW, Allred DC, Anderson BO et al (2012) Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 10(7):821-829
6. Dehdashti F, Mortimer JE, Siegel BA et al (1995) Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med 36(10):1766-1774
7. Linden HM, Ramsey S, Anderson N (2004) An ounce of prevention or a pound of cure? Investing to improve breast cancer outcomes for African American women. J Clin Oncol 22(13):2517-2518
8. Linden HM, Link JM, Stekhova S et al (2005) Serial 18F-fluoroestradiol positron emission tomography (FES PET) measures estrogen receptor binding during endocrine therapy. Breast Cancer Res Treat 94(Suppl 1):S1-S287
9. Linden HM, Stekhova SA, Link JM et al (2006) Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol 24(18):2793-2799
10. Mankoff DA, Peterson LM, Tewson TJ et al (2001) [18F]fluoroestradiol radiation dosimetry in human PET studies. J Nucl Med 42(4):679-684
11. Peterson LM, Kurland BF, Link JM et al (2011) Factors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer. Nucl Med Biol 38(7):969-978
12. Mintun MA, Welch MJ, Siegel BA et al (1988) Breast cancer: PET imaging of estrogen receptors. Radiology 169(1):45-48
13. Peterson LM, Mankoff DA, Lawton T et al (2008) Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol. J Nucl Med 49(3):367-374
14. Mortimer JE, Dehdashti F, Siegel BA et al (2001) Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 19(11):2797-2803
15. Mortimer JE, Dehdashti F, Siegel BA et al (1996) Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta- estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res 2(6):933-939
16. Lim JL, Zheng L, Berridge MS, Tewson TJ (1996) The use of 3-methoxymethyl-16 beta, 17 beta-epiestriol-O-cyclic sulfone as the precursor in the synthesis of F-18 16 alpha-fluoroestradiol.NuclMed Biol 23(7):911-915
17. Romer J, Fuchtner F, Steinbach J, Johannsen B (1999) Automated production of 16alpha-[18F]fluoroestradiol for breast cancer imaging. Nucl Med Biol 26(4):473-479
18. Romer J, Fuchtner F, Steinbach J, Kasch H (2001) Automated synthesis of 16alpha-[18F]fluoroestradiol-3,17beta-disulphamate. Appl Radiat Isot 55(5):631-639
19. Mankoff DA, Tewson TJ, Eary JF (1997) Analysis of blood clearance and labeled metabolites for the estrogen receptor tracer [F-18]-16 alpha-fluoroestradiol (FES). Nucl Med Biol 24(4):341-348
20. Kurland BF, Peterson LM, Lee JH et al (2011) Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET. J Nucl Med 52(10):1541-1549
21. Dehdashti F, Mortimer JE, Trinkaus K et al (2009) PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat 113(3):509-517
22. van Kruchten M, Glaudemans AW, de Vries EF et al (2012) PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma. J Nucl Med 53(2):182-190
23. Thie JA, Hubner KF, Smith GT (2000) The diagnostic utility of the lognormal behavior of PET standardized uptake values in tumors. J Nucl Med 41(10):1664-1672
24. Mankoff DA (2009) Molecular imaging to select cancer therapy and evaluate treatment response. Q J Nucl Med Mol Imaging 53(2):181-192
25. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228-247
26. Stafford SE, Gralow JR, Schubert EK et al (2002) Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy. Acad Radiol 9(8):913-921
27. Specht JM, Tam SL, Kurland BF et al (2007) Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP). Breast Cancer Res Treat 105(1):87-94
28. Gennari A, Donati S, Salvadori B et al (2000) Role of 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients. Clin Breast Cancer 1(2):156-161, discussion 162-153
29. Tateishi U, Gamez C, Dawood S et al (2008) Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. Radiology 247(1):189-196
30. Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50(Suppl 1):122S-150S
31. Porter PL, El-Bastawissi AY, Mandelson MT et al (1999) Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 91(23):2020-2028
32. Porter PL, Lund MJ, Lin MG et al (2004) Racial differences in the expression of cell cycle-regulatory proteins in breast carcinoma. Cancer 100(12):2533-2542
33. Porter PL, Malone KE, Heagerty PJ et al (1997) Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 3(2):222-225
34. Yaziji H, Goldstein LC, Barry TS et al (2004) HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 291(16):1972-1977
35. Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17(5):1474-1481
36. Lancaster H (1961) Significance tests in discrete distributions. J Am Stat Assoc 56:226-234